DXR Daxor Corporation
USHealthcareAs of 2026-07-10 16:00
Why DXR matters now
Daxor Corporation (DXR) is a US stock in Healthcare. The latest InvestLog snapshot shows $10.53 with +4.15% on the session and $53.1M in market capitalization; recent performance reads 1-month -14.17% and YTD -33.90%.
The latest financial table shown here is Q4 2025, with revenue of $131.8K, net income of $9.5M, and EPS of $1.89. Investors can compare that operating picture with valuation signals such as P/E 4.91 and FCF yield 0.3%.
The latest indexable market news headline is "Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $23.00; recent insider activity includes Feldschuh Michael Richard filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
4.91
PEG
0.06
P/B
1.08
P/S
327.09
EV/EBITDA
5.16
DCF Value
$-0.03
FCF Yield
0.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-57.5%
Operating Margin
6174.2%
Net Margin
6105.3%
ROE
22.5%
ROA
19.9%
ROIC
20.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $131.8K | $9.5M | $1.89 |
| FY 2025 | $503.4K | $9.2M | $1.84 |
| Q2 2025 | $18.3K | $-369.7K | $-0.07 |
| Q4 2024 | $695.3K | $2.2M | $0.44 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$23.00
Target (Median)
$23.00
Target Range
$23.00 - $23.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
0.26
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.